The USA's Generex has suggested its Oral-Lyn oral insulin spray may address suggestions made in the consensus algorithm for type 2 diabetes treatment published by the American Diabetes Association and the European Association for the Study of Diabetes in the on-line journal Diabetes Care.
A joint panel of ADA and EASD experts updated the treatment recommendations for type 2 diabetes in a consensus statement that provides guidance to health care providers. Generex says that Oral-lyn, which delivers insulin into the mouth using the firm's RapidMist drug delivery device: is a fast, effective and pain-free alternative to prandial insulin injections; can augment the early intervention insulin therapy for diabetes contemplated by the algorithm; and assist in delaying the progression of the disease and the onset of its myriad complications. Oral-lyn is presently in global Phase III trials, with 260 subjects enrolled at 69 sites in seven countries.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze